Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents.

Trial Profile

Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Daunorubicin liposomal (Primary) ; Cladribine; Cytarabine; Etoposide; Idarubicin; Mitoxantrone; Tretinoin
  • Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms AML-BFM 2004
  • Most Recent Events

    • 23 May 2013 Results of this study were published online in Blood, according to an American Society of Hematology media release.
    • 06 Jun 2012 New source identified and integrated (DRKS00003776: German Clinical Trials Register).
    • 22 May 2012 Planned end date changed from 1 Feb 2014 to 1 Mar 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top